Jyothy Labs Ltd

Jyothy Labs Ltd has issued an addendum to its public announcement regarding the buyback of equity shares. The Buyback Committee has approved an increase in the buyback price from ₹215 to ₹240 per equity share. Concurrently, the maximum number of equity shares to be bought back has been reduced from 68,37,210 to 61,25,000 shares. This represents approximately 1.67% of the company's total paid-up share capital. The buyback will be conducted on a proportionate basis through the tender offer route, in accordance with SEBI regulations. An addendum to the public announcement will be published in various newspapers and made available on the company's and regulatory websites.

Jyothy Labs Ltd's Board of Directors, in a meeting held on November 4, 2026, approved a buyback of equity shares through a tender offer route. The company plans to buy back up to 68,37,210 equity shares at a price of ₹215 per share, for an aggregate amount of up to ₹147 crore. This buyback represents 1.86% of the total equity share capital and is within the 10% limit for board-approved buybacks. The record date for determining eligible shareholders is fixed as November 11, 2026. The promoter and promoter group have expressed their intention not to participate in the buyback. The company also approved the unaudited financial results for the quarter and half-year ended September 30, 2026.

Jyothy Labs Limited reported its unaudited financial results for Q2 FY27, with Revenue from Operations at ₹760 crore, a 3.3% increase year-on-year. Excluding the Pril and Fa businesses, revenue grew by 12.4% in value and 8.1% in volume. The company faced significant input cost inflation, impacting Operating EBITDA to ₹19.2 crore and EBITDA margin to 2.5%. Profit After Tax stood at ₹10.6 crore. For the half-year ended September 30, 2026, Revenue from Operations was ₹1,533 crore (3.1% growth), Operating EBITDA was ₹83.9 crore (5.5% margin), and Profit After Tax was ₹58.2 crore. The Fabric Care segment grew 10.4% and Home Care (excluding Pril) grew 15.3%, with new product launches in both segments. Management is focused on margin recovery through pricing, efficiencies, and cost discipline.

Jyothy Labs Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also approved a buyback of up to 68,37,210 equity shares, representing 1.86% of the total paid-up equity share capital, at a price of ₹215 per share. The total buyback amount is up to ₹147 crore. The record date for determining eligibility for the buyback has been set as November 11, 2026. The promoter and promoter group have expressed their intention not to participate in the buyback. A buyback committee has been formed to manage the process.

Jyothy Labs' standalone PAT for Q2 FY27 (quarter ended September 30, 2026) fell 87.9% YoY to ₹10.60 Cr from ₹87.76 Cr, and 77.7% QoQ from ₹47.64 Cr, even though revenue from operations grew 3.3% YoY to ₹760.04 Cr (down 1.7% QoQ from ₹773.40 Cr). EPS fell to ₹0.29 from ₹2.39 a year ago and ₹1.30 last quarter. NPM (PAT/total income) collapsed to 1.37% from 11.65% YoY and 6.02% QoQ; OPM (PBT+finance cost/total income) fell to 2.28% from 16.07% YoY and 8.36% QoQ. No consolidated statement is filed, so these standalone figures are the primary — and only — basis for this result. The squeeze sits almost entirely on cost of materials consumed, which rose to 59.8% of revenue (₹454.75 Cr) from 52.1% a year ago (₹383.78 Cr) — an 18.5% YoY jump in raw-material cost against 3.3% revenue growth. A finished-goods inventory swing added further pressure: the inventory line moved from a ₹29.50 Cr cost credit a year ago to a ₹11.62 Cr charge this quarter, a ₹41 Cr adverse swing. By segment, Home Care (dishwash, mosquito repellents, aerosols) swung to a ₹12.83 Cr segment loss from a ₹39.48 Cr profit a year ago on revenue down 7.1% YoY to ₹282.38 Cr. Fabric Care, the largest segment, grew revenue 10.4% YoY to ₹386.58 Cr but segment PBT fell 67.1% YoY to ₹23.88 Cr. Personal Care was the lone bright spot, PBT up 152% YoY to ₹5.56 Cr on 11.2% revenue growth. Advertisement and sales-promotion spend was cut 8.1% YoY to ₹56.52 Cr, a lever management appears to have pulled to partially offset the cost hit. Management's prior (Q1 FY27) concall guidance flagged exactly this: EBITDA margins under pressure through H1, with "no immediate relief anticipated in Q2" as high-cost inventory works through the system, and recovery only expected from October. On that narrow point the quarter is consistent with what was flagged. But the broader FY27 guidance of double-digit revenue growth (ex-Pril and franchise) is tracking well short — H1 FY27 cumulative revenue grew just 3.1% YoY (₹1,533.44 Cr) and H1 PAT fell 68.4% YoY (₹58.24 Cr), meaning H2 would need to accelerate sharply to reach a double-digit full-year number. A web search found no specific analyst consensus or brokerage preview published ahead of this Q2 FY27 print, so the result cannot be benchmarked against street estimates; CARE Ratings reaffirmed the company's AA/Stable long-term facility rating on September 25, 2026, and the company separately recognised a ₹6.63 Cr insurance claim for the Patiala warehouse fire in late September — both minor relative to the scale of the margin miss. No company press release accompanied this filing beyond the regulatory results, so there is no management framing to reconcile against the numbers. The same board meeting approved a ₹147 Cr tender-offer buyback of up to 68.37 lakh shares (1.86% of paid-up equity) at ₹215/share, with the promoter group confirming it will not participate and November 11, 2026 set as the record date. The buyback follows four consecutive quarters of YoY profit decline and sits alongside management's own guidance that margin relief is a Q3/Q4 story, not a Q2 one — the next print is the test of whether that recovery materialises.

Jyothy Labs Ltd has announced that its Board of Directors meeting is scheduled for November 4, 2026. The board will consider and approve a proposal for the buyback of the company's fully paid-up equity shares. This decision aligns with the Companies Act, 2013, and SEBI (Buy-Back of Securities) Regulations, 2018. The trading window for dealing in the company's securities will remain closed until 48 hours after the outcome of the board meeting is disclosed.

Jyothy Labs Limited has announced that its Board of Directors will convene on Wednesday, November 4, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results for the quarter and half-year ended September 30, 2026. These results will be subject to a limited review by the company's Statutory Auditors. The company has also made this information available on its website.

Jyothy Labs Limited has announced the settlement of its insurance claim related to a fire incident at its C&FA-operated warehouse in Patiala, Punjab. The company claimed ₹7.33 Crores and has received ₹6.63 Crores from ICICI Lombard General Insurance Co. Limited. Following the fire, Jyothy Labs took immediate steps to clear the affected area and arrange for alternate warehousing facilities, ensuring business continuity with no material disruption. The company stated that, apart from the insurance settlement, there is no other material financial impact.

Jyothy Labs Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with the company's Code of Conduct and will be effective from October 1, 2026. The window will remain shut until 48 hours after the public announcement of the financial results for the second quarter and half year ending September 30, 2026. This measure is standard practice to prevent insider trading ahead of financial disclosures.

Jyothy Labs Ltd has received a reaffirmation of its long-term bank facilities rating from CARE Ratings Limited. The rating stands at CARE AA with a stable outlook, indicating a low risk of default. This reaffirmation pertains to the company's long-term bank facilities amounting to ₹250 crores. The stable outlook suggests that CARE Ratings expects the company's financial health and operational performance to remain consistent in the foreseeable future, providing a positive signal to investors regarding the company's creditworthiness.